Nesiritide for secondary pulmonary hypertension in patients with end-stage heart failure

American Journal of Health-System Pharmacy

Volumn 62, Issue 6, 2005, Pages 606-609

  O'Dell, Kate M ^a,b   Kalus, James S ^c,d   Kucukarslan, Suzan ^e   Czerska, Barbara ^f  

^a UNIVERSITY OF THE PACIFIC   (United States)

^b DAVID GRANT MEDICAL CENTER   (United States)

^c WAYNE STATE UNIVERSITY   (United States)

^d Department of Pharmacy Services ^*

^e Department of Pharmacy Services

^f HFH   (United States)

Author keywords

Cardiac drugs; Combined therapy; Heart failure; Hypertension; Nesiritide; Toxicity

Indexed keywords

CREATININE; DOBUTAMINE; INOTROPIC AGENT; LOOP DIURETIC AGENT; MILRINONE; NESIRITIDE;

ADULT; ARTICLE; CLINICAL ARTICLE; CREATININE BLOOD LEVEL; DYSPNEA; FEMALE; HEART FAILURE; HEART INDEX; HEMODYNAMICS; HUMAN; HYPOTENSION; KIDNEY FUNCTION; LUNG ARTERY PRESSURE; LUNG CAPILLARY PRESSURE; MALE; MEAN ARTERIAL PRESSURE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RETROSPECTIVE STUDY; SWAN GANZ CATHETER;

EID: 15044352863     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajhp/62.6.606     Document Type: Article

References (12)

1. Heart disease and stroke statistics-2003 update. Dallas: American Heart Association; 2002.
2. Murali S, Kormos RL, Uretsky BF et al. Preoperative pulmonary hemodynamics and early mortality after orthotropic cardiac transplantation: the Pittsburgh experience. Am Heart J. 1993; 126:896-904.
3. Cimato TR, Jessup M. Recipient selection in cardiac transplantation: contraindications and risk factors for mortality. J Heart Lung Transplant. 2002; 21:1161-73.
4. Hunt SA. Pulmonary hypertension in severe congestive heart failure: how important is it? J Heart Lung Transplant. 1997; 16:S13-5.
5. Wei CM, Heublein DM, Perrella MA et al. Natriuretic peptide system in human heart failure. Circulation. 1993; 88:1004-9.
6. Klinger JR, Warburton RR, Pietras L et al. Brain natriuretic peptide inhibits hypoxic pulmonary hypertension in rats. J Appl Physiol. 1998; 84:1646-52.
7. VMAC Investigators. Intravenous nesiritide vs. nitroglycerin for treatment of congestive heart failure. A randomized controlled trial. JAMA. 2002; 287:1531-40.
8. Nesiritide Study Group. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. N Engl J Med. 2000; 343:246-53.
9. Mills RM, LeJemtel TH, Horton DP et al. Sustained hemodynamic effects of an infusion of nesiritide (human b-type natriuretic peptide) in heart failure: a randomized, double-blind, placebo-controlled clinical trial. Natrecor Study Group. J Am Coll Cardiol. 1999; 34:155-62.
10. Hill JA, Hsu K, Aranda, Jr, JM et al. Sustained use of nesiritide to aid in bridging to heart transplant. Clin Cardiol. 2003; 26:211-4.
11. Bhat G, Costea A. Reversibility of medically unresponsive pulmonary hypertension with nesiritide in a cardiac transplant recipient. ASAIO J. 2003; 49:608-10.
12. Smull DL, Jorde UP. Concomitant use of nesiritide and milrinone in decompensated congestive heart failure. Am J Health-Syst Pharm. 2005; 62:291-5.